[ad_1]
A plaster that sticks to the inside of the mouth will revolutionize the treatment of painful oral ulcers.
The patch slowly releases steroids directly onto the ulcer and forms a protective barrier to accelerate healing.
The technology will soon begin the second phase of testing at several sites in the United Kingdom and the United States, including the Charles Clifford Hospital in Sheffield.
Until now, painful ulcers would be treated with anesthetic creams, gels or mouthwashes that swell around the mouth, making them less effective, said researchers from Sheffield University.
Special polymers in the new patch stick to moist surfaces for a long time, while the material flexes to fit the shape of the patient's mouth.
A plaster that sticks to the inside of the mouth will revolutionize the treatment of painful oral ulcers. File image used
The Plaster Novel is a revolutionary therapy for the treatment of ulcers, which can range from 2 to 10 mm in diameter and can last from two to six weeks, appearing in groups of up to 30 at a time in some cases.
It treats recurrent mouth ulcers, known medically as recurrent mouth stomatitis, that affect one to two percent of the population.
Plaster also works for oral lichen planus (OLP), an eruption that causes painful burns and gums and can last several years in the mouth.
Dr. Craig Murdoch, researcher in Oral Biology and lead author of the research, said: "Chronic inflammatory diseases such as OLP and RAS, which cause erosive and painful oral lesions, have a considerable impact on the quality of life.
Current treatments include the use of steroids in the form of mouthwashes, creams or ointments, but these are often ineffective due to inadequate medical contact times with the lesion.
The patch slowly releases the steroids directly to the ulcer (image of the file used) and forms a protective barrier to accelerate healing
"The patch acts like a plaster inside your mouth, which means it's very effective at directly targeting the specific area and forming a protective barrier.
"The patients who tested the patch found it very comfortable to wear and they were really happy with the length of time that made it particularly effective.
The biotech company Dermtreat is going ahead with this technology after receiving 13.3 million pounds sterling ($ 17.7 million) in venture capital investments.
Jens Hansen, Managing Director of Dermtreat A / S, added, "Our company is very confident that we will soon be getting regulatory approval for the first adhesive drug delivery technology to address urgent clinical needs in oral medicine. dental.
The patch uses a steroid called Clobetasol-17-propionate that is also used to treat eczema and psoriasis, and is often used in shampoos, lotions, and skin sprays.
[ad_2]
Source link
